• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ELX
Click for more information
3.09% 50.0¢

ELLEX MEDICAL LASERS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
ELX Ellex iTrack featured in the 8th WGC in Melbourne28/03/19
ELX LiGHT Trial Shows SLT More EffectivePRICE SENSITIVE12/03/19
ELX Investor Presentation FY2019 H1PRICE SENSITIVE22/02/19
ELX Half Yearly Report and AccountsPRICE SENSITIVE22/02/19
ELX Ellex H1 FY19 Investor Conference Call Details08/02/19
ELX ELX commence trading on USA OTCQX21/12/18
ELX Results of Meeting28/11/18
ELX Sales Update at AGMPRICE SENSITIVE28/11/18
ELX 2018 AGM Chair Script28/11/18
ELX 2018 CEO AGM PresentationPRICE SENSITIVE28/11/18
ELX Change in substantial holding05/11/18
ELX Notice of Annual General Meeting/Proxy Form26/10/18
ELX Annual Report to shareholders/Letter to Shareholders26/10/18
ELX Ellex 2RT Sales & Marketing Initiatives at AAOPRICE SENSITIVE26/10/18
ELX Ellex appoints Dr David Lubeck as Chief Medical Officer18/10/18
ELX ELX US Institutional Roadshow Oct 201808/10/18
ELX ELX LEAD trial investor presentationPRICE SENSITIVE21/09/18
ELX ELX LEAD trial investor call20/09/18
ELX ELX LEAD Clinical trial resultsPRICE SENSITIVE20/09/18
ELX Corporate Governance Statement & 4G30/08/18
ELX ELX FY18 ASX Release & Investor PresentationPRICE SENSITIVE30/08/18
ELX Full Year Statutory AccountsPRICE SENSITIVE30/08/18
ELX Ellex on recent MIGS device withdrawlPRICE SENSITIVE30/08/18
ELX Trading Update for Year Ended 30th June 2018PRICE SENSITIVE27/07/18
ELX Appointment of President Ellex iTrack11/07/18
ELX Initial Director's Interest Notice02/07/18
ELX Appointment of Directors02/07/18
ELX Change of Director's Interest Notice01/06/18
ELX Change in substantial holding22/05/18
ELX Final Director's Interest Notice15/05/18
ELX Director Appointment/Resignation15/05/18
ELX Change of Director's Interest Notice14/05/18
ELX Glaucoma Business FY18Q3 Sales UpdatePRICE SENSITIVE16/04/18
ELX Glaucoma Technologies at US Tradeshow ASCRS 201810/04/18
ELX 2RT at European Laser Innovation Forum 201823/03/18
ELX Ellex Presentation at Oppenheimer Conference19/03/18
ELX Additional Financial Information for Half Year09/03/18
ELX S&P DJ Indices Announces March Quarterly RebalancePRICE SENSITIVE09/03/18
ELX Ellex at American Glaucoma Society Meeting, New York City07/03/18
ELX Half Year Accounts for 31 December 2017PRICE SENSITIVE27/02/18
ELX Trading Update for Half Year Ended 31 December 2017PRICE SENSITIVE05/02/18
ELX Ceasing to be a substantial holder17/01/18
ELX Becoming a substantial holder15/01/18
ELX Revised Appendix 3B04/01/18
ELX Share Purchase Plan Closure and Tranche 2 PlacementPRICE SENSITIVE22/12/17
ELX Appendix 3B - Share Purchase Plan22/12/17
ELX Becoming a substantial holder18/12/17
ELX Cleansing Statement 14 December 201714/12/17
ELX Appendix 3B13/12/17
ELX Results of Meeting08/12/17
ELX Results of Meeting28/11/17
ELX 2017 AGM script28/11/17
ELX 2017 AGM Script28/11/17
ELX 2017 CEO's AGM PresentationPRICE SENSITIVE28/11/17
ELX Extension of Closing Date of Share Purchase PlanPRICE SENSITIVE23/11/17
ELX Update Following Major USA Tradeshow17/11/17
ELX Share Purchase Plan and Application Form14/11/17
ELX Availability of Ellex SPP offer documents14/11/17
ELX Cleansing Notice - Share Purchase Plan14/11/17
ELX Completion of Tranche 1 PlacementPRICE SENSITIVE09/11/17
ELX Cleansing Statement 8th November 201709/11/17
ELX Appendix 3B09/11/17
ELX Cleansing Statement 7th November allocation08/11/17
ELX Appendix 3B07/11/17
ELX Notice of Extraordinary General Meeting07/11/17
ELX Equity Captial for Ellex iTrack ExpansionPRICE SENSITIVE03/11/17
ELX Trading HaltPRICE SENSITIVE01/11/17
ELX Annual Report to Shareholders27/10/17
ELX Notice of Annual General Meeting27/10/17
ELX Ellex Corporate Presentation20/10/17
ELX Ellex iTrack Sales for Quarter Ended 30 September 2017PRICE SENSITIVE03/10/17
ELX Corporate Governance Statement29/09/17
ELX Appendix 4G29/09/17
ELX Full Year Audited Statutory Accounts29/09/17
ELX Change in substantial holding from AEF28/09/17
ELX Ellex iTrack Production Capacity ExpansionPRICE SENSITIVE01/09/17
ELX Ellex Strengthens IP Portfolio for 2RTPRICE SENSITIVE29/08/17
ELX Full Year FY17 Audited ResultsPRICE SENSITIVE25/08/17
ELX ELX Milestone achieved for Ellex iTrack in ChinaPRICE SENSITIVE31/07/17
ELX Ellex FY17 Trading Update EarningsPRICE SENSITIVE28/07/17
ELX ELX FY17 Trading Update EarningsPRICE SENSITIVE28/07/17
ELX Ellex Company UpdatePRICE SENSITIVE25/07/17
ELX Ellex Reflex Technology published in peer-review journalPRICE SENSITIVE21/07/17
ELX Ellex Sales Trading UpdatePRICE SENSITIVE06/07/17
ELX Ellex iTrack Sales and Marketing UpdatePRICE SENSITIVE22/06/17
ELX Ellex iTrack approval in China extendedPRICE SENSITIVE06/06/17
ELX Ellex acquires future royalty for iTrackPRICE SENSITIVE30/05/17
ELX ELX Site Tour of Institutional Shareholders & Analysts19/05/17
ELX Change in substantial holding from AEF11/05/17
ELX Ellex iTrack ASCRSPRICE SENSITIVE05/05/17
ELX S&P DJ Indices Announces March Quarterly RebalancePRICE SENSITIVE10/03/17
ELX ELX presentation to Ophthalmology Futures Asian Forum 201701/03/17
ELX ELX 1H FY17 ASX Release & Investor PresentationPRICE SENSITIVE27/02/17
ELX Half Yearly Report & AccountsPRICE SENSITIVE27/02/17
ELX Clarification to Trading Update for Half-Year Ended 311216PRICE SENSITIVE02/02/17
ELX Trading Update for Half-Year Ended 31 December 2016PRICE SENSITIVE02/02/17
ELX Ellex iTrack commencement of clincal training in ChinaPRICE SENSITIVE15/12/16
ELX Amended Appendix 3B09/12/16
ELX Cleansing Statement09/12/16
ELX Appendix 3B09/12/16
ELX Ellex iTrack featured in the 8th WGC in Melbourne
28/03/19
ELX LiGHT Trial Shows SLT More Effective
12/03/19PRICE SENSITIVE
ELX Investor Presentation FY2019 H1
22/02/19PRICE SENSITIVE
ELX Half Yearly Report and Accounts
22/02/19PRICE SENSITIVE
ELX Ellex H1 FY19 Investor Conference Call Details
08/02/19
ELX ELX commence trading on USA OTCQX
21/12/18
ELX Results of Meeting
28/11/18
ELX Sales Update at AGM
28/11/18PRICE SENSITIVE
ELX 2018 AGM Chair Script
28/11/18
ELX 2018 CEO AGM Presentation
28/11/18PRICE SENSITIVE
ELX Change in substantial holding
05/11/18
ELX Notice of Annual General Meeting/Proxy Form
26/10/18
ELX Annual Report to shareholders/Letter to Shareholders
26/10/18
ELX Ellex 2RT Sales & Marketing Initiatives at AAO
26/10/18PRICE SENSITIVE
ELX Ellex appoints Dr David Lubeck as Chief Medical Officer
18/10/18
ELX ELX US Institutional Roadshow Oct 2018
08/10/18
ELX ELX LEAD trial investor presentation
21/09/18PRICE SENSITIVE
ELX ELX LEAD trial investor call
20/09/18
ELX ELX LEAD Clinical trial results
20/09/18PRICE SENSITIVE
ELX Corporate Governance Statement & 4G
30/08/18
ELX ELX FY18 ASX Release & Investor Presentation
30/08/18PRICE SENSITIVE
ELX Full Year Statutory Accounts
30/08/18PRICE SENSITIVE
ELX Ellex on recent MIGS device withdrawl
30/08/18PRICE SENSITIVE
ELX Trading Update for Year Ended 30th June 2018
27/07/18PRICE SENSITIVE
ELX Appointment of President Ellex iTrack
11/07/18
ELX Initial Director's Interest Notice
02/07/18
ELX Appointment of Directors
02/07/18
ELX Change of Director's Interest Notice
01/06/18
ELX Change in substantial holding
22/05/18
ELX Final Director's Interest Notice
15/05/18
ELX Director Appointment/Resignation
15/05/18
ELX Change of Director's Interest Notice
14/05/18
ELX Glaucoma Business FY18Q3 Sales Update
16/04/18PRICE SENSITIVE
ELX Glaucoma Technologies at US Tradeshow ASCRS 2018
10/04/18
ELX 2RT at European Laser Innovation Forum 2018
23/03/18
ELX Ellex Presentation at Oppenheimer Conference
19/03/18
ELX Additional Financial Information for Half Year
09/03/18
ELX S&P DJ Indices Announces March Quarterly Rebalance
09/03/18PRICE SENSITIVE
ELX Ellex at American Glaucoma Society Meeting, New York City
07/03/18
ELX Half Year Accounts for 31 December 2017
27/02/18PRICE SENSITIVE
ELX Trading Update for Half Year Ended 31 December 2017
05/02/18PRICE SENSITIVE
ELX Ceasing to be a substantial holder
17/01/18
ELX Becoming a substantial holder
15/01/18
ELX Revised Appendix 3B
04/01/18
ELX Share Purchase Plan Closure and Tranche 2 Placement
22/12/17PRICE SENSITIVE
ELX Appendix 3B - Share Purchase Plan
22/12/17
ELX Becoming a substantial holder
18/12/17
ELX Cleansing Statement 14 December 2017
14/12/17
ELX Appendix 3B
13/12/17
ELX Results of Meeting
08/12/17
ELX Results of Meeting
28/11/17
ELX 2017 AGM script
28/11/17
ELX 2017 AGM Script
28/11/17
ELX 2017 CEO's AGM Presentation
28/11/17PRICE SENSITIVE
ELX Extension of Closing Date of Share Purchase Plan
23/11/17PRICE SENSITIVE
ELX Update Following Major USA Tradeshow
17/11/17
ELX Share Purchase Plan and Application Form
14/11/17
ELX Availability of Ellex SPP offer documents
14/11/17
ELX Cleansing Notice - Share Purchase Plan
14/11/17
ELX Completion of Tranche 1 Placement
09/11/17PRICE SENSITIVE
ELX Cleansing Statement 8th November 2017
09/11/17
ELX Appendix 3B
09/11/17
ELX Cleansing Statement 7th November allocation
08/11/17
ELX Appendix 3B
07/11/17
ELX Notice of Extraordinary General Meeting
07/11/17
ELX Equity Captial for Ellex iTrack Expansion
03/11/17PRICE SENSITIVE
ELX Trading Halt
01/11/17PRICE SENSITIVE
ELX Annual Report to Shareholders
27/10/17
ELX Notice of Annual General Meeting
27/10/17
ELX Ellex Corporate Presentation
20/10/17
ELX Ellex iTrack Sales for Quarter Ended 30 September 2017
03/10/17PRICE SENSITIVE
ELX Corporate Governance Statement
29/09/17
ELX Appendix 4G
29/09/17
ELX Full Year Audited Statutory Accounts
29/09/17
ELX Change in substantial holding from AEF
28/09/17
ELX Ellex iTrack Production Capacity Expansion
01/09/17PRICE SENSITIVE
ELX Ellex Strengthens IP Portfolio for 2RT
29/08/17PRICE SENSITIVE
ELX Full Year FY17 Audited Results
25/08/17PRICE SENSITIVE
ELX ELX Milestone achieved for Ellex iTrack in China
31/07/17PRICE SENSITIVE
ELX Ellex FY17 Trading Update Earnings
28/07/17PRICE SENSITIVE
ELX ELX FY17 Trading Update Earnings
28/07/17PRICE SENSITIVE
ELX Ellex Company Update
25/07/17PRICE SENSITIVE
ELX Ellex Reflex Technology published in peer-review journal
21/07/17PRICE SENSITIVE
ELX Ellex Sales Trading Update
06/07/17PRICE SENSITIVE
ELX Ellex iTrack Sales and Marketing Update
22/06/17PRICE SENSITIVE
ELX Ellex iTrack approval in China extended
06/06/17PRICE SENSITIVE
ELX Ellex acquires future royalty for iTrack
30/05/17PRICE SENSITIVE
ELX ELX Site Tour of Institutional Shareholders & Analysts
19/05/17
ELX Change in substantial holding from AEF
11/05/17
ELX Ellex iTrack ASCRS
05/05/17PRICE SENSITIVE
ELX S&P DJ Indices Announces March Quarterly Rebalance
10/03/17PRICE SENSITIVE
ELX ELX presentation to Ophthalmology Futures Asian Forum 2017
01/03/17
ELX ELX 1H FY17 ASX Release & Investor Presentation
27/02/17PRICE SENSITIVE
ELX Half Yearly Report & Accounts
27/02/17PRICE SENSITIVE
ELX Clarification to Trading Update for Half-Year Ended 311216
02/02/17PRICE SENSITIVE
ELX Trading Update for Half-Year Ended 31 December 2016
02/02/17PRICE SENSITIVE
ELX Ellex iTrack commencement of clincal training in China
15/12/16PRICE SENSITIVE
ELX Amended Appendix 3B
09/12/16
ELX Cleansing Statement
09/12/16
ELX Appendix 3B
09/12/16
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.